Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0HCQQE
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
XNW28012
|
|||||
| Synonyms |
XNW28012; XNW28; YL204
Click to Show/Hide
|
|||||
| Organization |
XNW Pharma (Sinovent) (Originator);MediLink Therapeutics (Originator)
|
|||||
| Drug Status |
Phase 3
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-tissue factor antibody
|
Antibody Info | ||||
| Antigen Name |
Tissue factor (F3)
|
Antigen Info | ||||
| Payload Name |
YL0010014
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
VK*G-NHCH2-O linker
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
pelitecan
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cervical cancer |
1 Trials
|
||||||||||
| Colorectal cancer |
1 Trials
|
||||||||||
| Ovarian cancer |
1 Trials
|
||||||||||
| Pancreatic cancer |
1 Trials
|
1 Trials
|
|||||||||
| Unspecific solid tumor |
1 Trials
|